Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 9/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553619 | 0.91 | AGTR2 (0.48) | AGTR2KMT2AFABP7FABP5 | |
| SCHEMBL21874030 | 0.91 | AGTR2 (0.48) | AGTR2KMT2AFABP7FABP5 | |
| SCHEMBL16095440 | 0.91 | AGTR2 (0.48) | AGTR2KMT2AFABP7FABP5 | |
| SCHEMBL5963754 | 0.91 | AGTR2 (0.48) | AGTR2KMT2AFABP7FABP5 | |
| SCHEMBL31210291 | 0.91 | AGTR2 (0.48) | AGTR2KMT2AFABP7FABP5 | |
| SCHEMBL8166482 | 0.89 | AGTR2 (0.42) | AGTR2L3MBTL1KMT2AFABP7FABP5 | |
| SCHEMBL16277190 | 0.86 | FFAR2 (0.45) | AGTR2L3MBTL1 | |
| SCHEMBL29400879 | 0.83 | AGTR2 (0.43) | AGTR2KMT2AFABP7FABP5 | |
| SCHEMBL29540218 | 0.82 | AGTR2 (0.42) | AGTR2KMT2AFABP7FABP5 | |
| SCHEMBL15083500 | 0.82 | AGTR2 (0.42) | AGTR2KMT2AFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | AGTR2 235/4885L3MBTL1 609/4885KMT2A 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.